Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Gileads primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions. Our portfolio of 13 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. Viread® (tenofovir disoproxil fumarate), the company's first agent approved for HIV infection, was also approved in 2008 for the treatment of chronic hepatitis B.
Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,000 employees. In 2009, Gileads annual revenues surpassed $7 billion. BusinessWeek ranked Gilead #1 in its 2009 listing of the 50 best-performing companies, up from #2 in 2008.